ライフサイエンスコーパス: bendamustine

1 e) proceeded to alloSCT after treatment with bendamustine.

2 phosphamide, vincristine, and prednisone, or bendamustine.

3 ed), BV plus dacarbazine (DTIC), and BV plus bendamustine.

4 s who received any amount of obinutuzumab or bendamustine.

5 of ibrutinib combined with rituximab (R) and bendamustine.

6 or for whom this treatment failed, received bendamustine 120 mg/m(2) as a 30-minute infusion on days

7 eived rituximab (44% versus 9%; P < 0.0001), bendamustine (22% versus 0%; P < 0.001), high-dose stero

8 Bendamustine 70 mg/m(2) days 1 and 4; bortezomib 1.3 mg/

9 on day 1 of a 21 day cycle, plus one dose of bendamustine (70 mg/m(2), 80 mg/m(2), or 90 mg/m(2)) on

10 e safety and efficacy of escalating doses of bendamustine (70, 90, 110, and 130 mg/m2 per day for 3 d

11 plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m(2) intravenously on days 1 and 2 f

12 uximab given in cycles of 4 weeks' duration (bendamustine: 70 mg/m(2) intravenously on days 2-3 in cy

13 MTD was bendamustine 75 mg/m(2) (days 1 and 2), lenalidomide 10

14 nts received rituximab 375 mg/m(2) day 1 and bendamustine 90 mg/m(2) days 1 and 2 for 4 cycles at a 2

15 th adequate organ function were treated with bendamustine 90 mg/m(2) days 1 and 4; rituximab 375 mg/m

16 8, and 15, cycle 1; day 1, cycles 2-6) plus bendamustine 90 mg/m(2) per day (days 1 and 2, cycles 1-

17 essment, and a total of 63 patients received bendamustine 90 mg/m(2).

18 day) for the first 3 days or to intravenous bendamustine (90 mg/m(2) per day) for the first 2 days o

19 Patients received R (375 mg/m(2)) on day 1, bendamustine (90 mg/m(2)) on days 1 and 2, and ibrutinib

20 d peripheral T-cell lymphoma, treatment with bendamustine alone only achieves modest improvements in

21 randomly assigned (194 to obinutuzumab plus bendamustine and 202 to bendamustine monotherapy).

22 2 deaths on study led to discontinuation of bendamustine and cessation of enrollment.

23 alone or rituximab combined with alkylators (bendamustine and cyclophosphamide), proteasome inhibitor

24 Newer agents, such as bendamustine and everolimus, can also be considered in t

25 hermore, NOX-A12 sensitizes CLL cells toward bendamustine and fludarabine in BMSC cocultures.

26 We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously untreated

27 actory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclopho

28 ival was 41.7 months (95% CI 34.9-45.3) with bendamustine and rituximab and 55.2 months (95% CI not e

29 sphamide, and rituximab group and 279 in the bendamustine and rituximab group.

30 ents with chronic lymphocytic leukaemia, but bendamustine and rituximab is associated with less toxic

31 nts and for patients with renal dysfunction, bendamustine and rituximab may be a better option.

32 h the objective to assess non-inferiority of bendamustine and rituximab to the standard therapy.

33 at the 2-year progression-free survival with bendamustine and rituximab was not 67.5% or less with a

34 mantle-cell lymphoma with the combination of bendamustine and rituximab.

35 ntially less toxic combination consisting of bendamustine and rituximab.

36 Trabectedin, bendamustine and the pyrrolobenzodiazepine dimer SG2000

37 Clinical trials with rituximab, bendamustine, and conjugate immunotoxins will reveal wha

38 d toxicity of the combination of bortezomib, bendamustine, and rituximab in patients with follicular

39 The combination of bortezomib, bendamustine, and rituximab is highly active in patients

40 een approved for CLL treatment (fludarabine, bendamustine, and the monoclonal antibodies alemtuzumab,

41 ne therapy); had received a purine analogue, bendamustine, anti-CD20 antibody, chlorambucil, or alemt

42 assigned to receive brentuximab vedotin plus bendamustine at the recommended phase 2 dose from phase

43 The combination of bendamustine (B) and rituximab (R) is efficacious, with

44 tment agents (interferon-alpha, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, lenalidom

45 Bendamustine-bortezomib-dexamethasone is active and well

46 conducted a multicenter phase 2 study of the bendamustine/bortezomib/rituximab combination.

47 upport current and future studies evaluating bendamustine combinations in relapsed and refractory HL.

48 atforms have changed in the past 5 years, as bendamustine combined with rituximab has rapidly become

49 or relapse within 24 months with a previous bendamustine-containing regimen, or haemopoietic stem-ce

50 nib treatment, and subsequent treatment with bendamustine, cytarabine, or lenalidomide failed to reve

51 Obinutuzumab plus bendamustine dosing was obinutuzumab 1000 mg (days 1, 8,

52 ultures, CAL-101 sensitizes CLL cells toward bendamustine, fludarabine, and dexamethasone.

53 Obinutuzumab plus bendamustine followed by obinutuzumab maintenance has im

54 e a rationale for combining fludarabine with bendamustine for patients with CLL.

55 received 1.8 mg/kg BV plus 90 or 70 mg/m(2) bendamustine for up to 6 cycles (dose reduced due to tox

56 ety and preliminary efficacy of obinutuzumab-bendamustine (G-B) or obinutuzumab fludarabine cyclophos

57 phase II study evaluated the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) as in

58 ths (IQR 12.1-31.0) in the obinutuzumab plus bendamustine group and 20.3 months (9.5-29.7) in the ben

59 vent-related deaths in the obinutuzumab plus bendamustine group and five (42%) of 12 in the bendamust

60 8%) of 194 patients in the obinutuzumab plus bendamustine group and in 123 (62%) of 198 patients in t

61 n 74 patients (38%) in the obinutuzumab plus bendamustine group and in 65 patients (33%) in the benda

62 rogressing patients in the obinutuzumab plus bendamustine group received obinutuzumab maintenance (10

63 utropenia (64 [33%] in the obinutuzumab plus bendamustine group vs 52 [26%] in the bendamustine monot

64 ximately 30 patients were to receive BV plus bendamustine; however, the incidence of serious adverse

65 Bendamustine hydrochloride is an alkylating agent with n

66 This study confirms the efficacy of bendamustine in heavily pretreated patients with HL.

67 the combination of brentuximab vedotin plus bendamustine in heavily pretreated patients with relapse

68 Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL).

69 nd the benefits of maintenance rituximab and bendamustine in older patients.

70 mg/kg brentuximab vedotin plus 70 mg/m(2) of bendamustine in one (4%) patient.

71 study evaluated the efficacy and toxicity of bendamustine in patients with B-cell non-Hodgkin's lymph

72 se 2 dose of ibrutinib in combination with R-bendamustine in patients with NHL is 560 mg.

73 his phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL.

74 d type II anti-CD20 monoclonal antibody, and bendamustine in this patient population.

75 mg/kg brentuximab vedotin plus 80 mg/m(2) of bendamustine in two (7%) patients and diffuse rash at 1.

76 pothesized that similar to cyclophosphamide, bendamustine-induced DNA damage will be inhibited by flu

77 Bendamustine is a newly approved and better-tolerated al

78 Bendamustine is a unique cytotoxic agent with structural

79 Bendamustine is approved in Germany for the treatment of

80 Despite activity, BV plus bendamustine is not a tolerable regimen in these patient

81 This first phase 1/2 trial testing bendamustine, lenalidomide, and dexamethasone as treatme

82 se 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeati

83 ituximab-refractory disease, suggesting that bendamustine may be the most effective drug available fo

84 significantly longer with obinutuzumab plus bendamustine (median not reached [95% CI 22.5 months-not

85 95% CI 22.5 months-not estimable]) than with bendamustine monotherapy (14.9 months [12.8-16.6]; hazar

86 m(2) per day (days 1 and 2, cycles 1-6), and bendamustine monotherapy dosing was 120 mg/m(2) per day

87 ndamustine group and five (42%) of 12 in the bendamustine monotherapy group were treatment related.

88 b plus bendamustine group vs 52 [26%] in the bendamustine monotherapy group), thrombocytopenia (21 [1

89 ustine group and in 65 patients (33%) in the bendamustine monotherapy group, and deaths due to advers

90 tine group and 20.3 months (9.5-29.7) in the bendamustine monotherapy group, progression-free surviva

91 roup and in 123 (62%) of 198 patients in the bendamustine monotherapy group.

92 zumab maintenance has improved efficacy over bendamustine monotherapy in rituximab-refractory patient

93 to obinutuzumab plus bendamustine and 202 to bendamustine monotherapy).

94 cles) with obinutuzumab plus bendamustine or bendamustine monotherapy, both given intravenously.

95 ts (33%) received fewer than three cycles of bendamustine, mostly because of disease progression.

96 t (six 28-day cycles) with obinutuzumab plus bendamustine or bendamustine monotherapy, both given int

97 ituximab and cyclophosphamide-dexamethasone, bendamustine, or bortezomib-dexamethasone provide durabl

98 nations with cyclophosphamide/dexamethasone, bendamustine, or bortezomib/dexamethasone provided durab

99 otherapy (fludarabine plus cyclophosphamide, bendamustine, or chlorambucil) and anti-CD20 antibody (r

100 istic effects when combined with cytarabine, bendamustine, or rituximab.

101 to ibrutinib or placebo in combination with bendamustine plus rituximab (289 in each group).

102 3 study evaluated the efficacy and safety of bendamustine plus rituximab (BR) vs a standard rituximab

103 oved progression-free survival compared with bendamustine plus rituximab alone in patients with relap

104 l interactive web response system to receive bendamustine plus rituximab for a maximum of six cycles

105 igned (1:1) by a web-based system to receive bendamustine plus rituximab given in cycles of 4 weeks'

106 TERPRETATION: Idelalisib in combination with bendamustine plus rituximab improved progression-free su

107 ibitor of Bruton's tyrosine kinase (BTK), to bendamustine plus rituximab in patients with previously

108 hosphoinositide-3-kinase delta inhibitor, to bendamustine plus rituximab in this population.

109 that previously reported with ibrutinib and bendamustine plus rituximab individually was noted.

110 Bendamustine plus rituximab is a standard of care for th

111 Bendamustine plus rituximab is often used in the relapse

112 C plus rituximab; CLL10: FC plus rituximab v bendamustine plus rituximab) were analyzed according to

113 In patients eligible for bendamustine plus rituximab, the addition of ibrutinib t

114 e excluded because of known poor response to bendamustine plus rituximab.

115 Single-agent bendamustine produced durable objective responses with a

116 However, the availability of bendamustine provides another effective treatment option

117 addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly p

118 Thirteen patients (29%) had their dose of bendamustine reduced.

119 ltaneous or prior addition of fludarabine to bendamustine resulted in maximum cytotoxicity assayed by

120 the significant activity and tolerability of bendamustine, rituximab, and bortezomib in patients with

121 fludarabine-rituximab, 7 (50%) responded to bendamustine-rituximab (3 CR and 4 PR).

122 r phase 3 clinical trial NHL1-2003 comparing bendamustine-rituximab (B-R) with rituximab, cyclophosph

123 In a single-arm, phase 2 clinical trial, bendamustine-rituximab (BR) demonstrated an overall resp

124 ynthesis of available evidence, we recommend bendamustine-rituximab as primary therapy for bulky dise

125 In conclusion, bendamustine-rituximab combination therapy is highly eff

126 The combination of bendamustine-rituximab was demonstrated to be noninferio

127 Bendamustine showed an encouraging high response rate ac

128 Bendamustine showed consistent efficacy independent of m

129 For BV plus bendamustine, the ORR was 100% and the CR rate was 88%.

130 Questions related to the optimization of bendamustine therapy, including dose and schedule, role

131 cells display resistance to doxorubicin and bendamustine, two drugs largely used in FL therapy, comp

132 Bendamustine was administered at a dose of 90 mg/m(2) on

133 on, and unscheduled DNA synthesis induced by bendamustine was blocked by fludarabine.

134 lation phase, the maximum-tolerated dose for bendamustine was not reached; the 90 mg/m(2) dose level

135 /kg of brentuximab vedotin and 90 mg/m(2) of bendamustine, which are the standard doses of the drugs

136 Bendamustine with bortezomib and dexamethasone was evalu

137 is study shows that brentuximab vedotin plus bendamustine, with a favourable safety profile, is an ac